An aimed application of Dysport (botulinum toxin A) in children with dynamic contractures helps to correct a foot deformity, to improve walking and to reach better quality of life for affected persons. It also produces a reduction in spasm frequency and spasm-induced pain.
Authors present their experiences with the management of children with cerebral palsy. A desirable reduction of spasticity by Dysport can also lead to an individual reduction of residual physiological function.
These facultative side effects are divided into local, systemic and functional side effects. Local side effects are: a) extension of paresis and b) appearance of haematoma or pain.
Systemic side effects may occur rarely. The temporary functional side effects can be divided into four groups: unmasking of underlying pathology, positive or negative effects and effects due to neurophysiological connections.